The CSIR and Laxai Life Sciences Private Limited have initiated phase II clinical trials of anti-helminitic drug ‘Niclosamide’ for the treatment of COVID-19 patients, a statement said on Sunday.
New Delhi: CSIR in collaboration with Laxai Life Sciences Pvt. Ltd., has initiated Phase-II clinical trial with anti-helminitic drug Niclosamide for treatment of Covid-19. The trial is a multi-centric, phase-II, randomized, open label clinical study
The trial is a multi-centric, randomised, open label clinical study to evaluate the efficacy, safety and tolerability of Niclosamide for treating hospitalised COVID-19 patients.
/PRNewswire/ Verified Market Research recently published a report, "Active Pharmaceutical Ingredient (API) Market" By Molecule (Small Molecule and Large.